Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Real-World study tests durvalumab combo for Tough-to-Treat endometrial cancer

NCT ID NCT06890273

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 28 times

Summary

This study is collecting real-world data from 150 women in Germany with advanced or recurrent endometrial cancer. Participants receive standard chemotherapy plus durvalumab, followed by maintenance therapy with durvalumab alone or with olaparib. The goal is to see how well this treatment works in everyday practice and how it affects quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Research Site

    RECRUITING

    Amberg, Germany

  • Research Site

    RECRUITING

    Bad Nauheim, Germany

  • Research Site

    RECRUITING

    Bautzen, Germany

  • Research Site

    RECRUITING

    Berlin, Germany

  • Research Site

    RECRUITING

    Bielefeld, Germany

  • Research Site

    RECRUITING

    Borna, Germany

  • Research Site

    RECRUITING

    Bottrop, Germany

  • Research Site

    RECRUITING

    Brandenburg an der Havel, Germany

  • Research Site

    RECRUITING

    Braunschweig, Germany

  • Research Site

    RECRUITING

    Cologne, Germany

  • Research Site

    RECRUITING

    Dessau, Germany

  • Research Site

    RECRUITING

    Dresden, Germany

  • Research Site

    RECRUITING

    Ebersberg, Germany

  • Research Site

    RECRUITING

    Essen, Germany

  • Research Site

    RECRUITING

    Goslar, Germany

  • Research Site

    RECRUITING

    Greifswald, Germany

  • Research Site

    RECRUITING

    Gütersloh, Germany

  • Research Site

    RECRUITING

    Heilbronn, Germany

  • Research Site

    RECRUITING

    Homburg, Germany

  • Research Site

    RECRUITING

    Hösbach, Germany

  • Research Site

    RECRUITING

    Krefeld, Germany

  • Research Site

    RECRUITING

    Kulmbach, Germany

  • Research Site

    RECRUITING

    Landshut, Germany

  • Research Site

    RECRUITING

    Leipzig, Germany

  • Research Site

    RECRUITING

    Limburg, Germany

  • Research Site

    RECRUITING

    Lüneburg, Germany

  • Research Site

    RECRUITING

    Magdeburg, Germany

  • Research Site

    RECRUITING

    Mainz, Germany

  • Research Site

    RECRUITING

    München, Germany

  • Research Site

    RECRUITING

    Neuss, Germany

  • Research Site

    RECRUITING

    Nuremberg, Germany

  • Research Site

    RECRUITING

    Plauen, Germany

  • Research Site

    RECRUITING

    Rotenburg (Wümme), Germany

  • Research Site

    RECRUITING

    Siegen, Germany

  • Research Site

    RECRUITING

    Solingen, Germany

  • Research Site

    RECRUITING

    Torgau, Germany

  • Research Site

    RECRUITING

    Traunstein, Germany

  • Research Site

    RECRUITING

    Unna, Germany

  • Research Site

    RECRUITING

    Weningerode, Germany

  • Research Site

    RECRUITING

    Winnenden, Germany

  • Research Site

    RECRUITING

    Witten, Germany

  • Research Site

    RECRUITING

    Worms, Germany

Conditions

Explore the condition pages connected to this study.

ENDOMETRIAL CANCER ENDOMETRIAL CANCER